Fulcrum’s Losmapimod Improves Multiple Measures, But Not Primary Endpoint
Secondary Endpoints May Matter More In FSHD Study
Executive Summary
The ReDUX4 study missed its biomarker-driven primary endpoint, making it unclear if an additional trial will be needed for regulatory submission.
You may also be interested in...
Finance Watch: Big Bucks For T-regs In Autoimmune Diseases, Inflammation
GentiBio closed a $157m series A venture capital round, while clinical trial innovator Reify Health raised a $220m series C and Neurelis secured $150m. Also, IPOs slowed in August, but Adagio and Eliem grossed $309.4m and $80m, respectively, and RNA firm Greenlight will go public in a $282m SPAC deal.
Acceleron Ends ACE-083 FSHD Testing After Phase II Failure
Acceleron ended testing of ACE-083 in facioscapulohumeral muscular dystrophy after the investigational drug missed Phase II endpoints.
AstraZeneca Pulls Plug On Ionis’ PCSK9 Candidate
While the Phase IIb SOLANO trial of ION449 met its primary endpoint, AstraZeneca had set a high bar of 70% LDL cholesterol reduction for competitiveness that the study did not hit.